Scott Veitch retweetledi

🔬 Breakthrough for late-stage Hodgkin lymphoma: NICE has approved brentuximab vedotin combination therapy as the first treatment specifically for previously untreated stage 3 or 4 classical Hodgkin lymphoma.
This could benefit 800 patients per year.
nice.org.uk/news/articles/…

English























